Stock events for Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals' stock (PCSA) has experienced significant volatility, declining by approximately 79.28% to 88% with a 52-week trading range between $1.76 and $19.63. In December 2025, the company announced preliminary Phase 2 data for its NGC-Cap therapy, leading to a stock surge of 23.8%. Also in December 2025, Processa Pharmaceuticals effected a one-for-twenty-five reverse stock split. In January 2026, the company completed enrollment of the 20th patient for an interim analysis in its Phase 2 NGC-Cap breast cancer study and attended the J.P. Morgan Healthcare Conference. In February 2026, SEC filings indicated Chiliz Group boosted its stake to 13%, and Intracoastal Capital LLC disclosed an 8.1% beneficial ownership stake; a term sheet for PCS12852 expired. In November 2025, Processa Pharmaceuticals announced a poster presentation of its adaptive Phase 2/3 PCS499 study at ASN Kidney Week 2025.
Demand Seasonality affecting Processa Pharmaceuticals, Inc.’s stock price
Processa Pharmaceuticals, Inc. does not exhibit typical demand seasonality for its products or services. The demand for its pipeline candidates is driven by clinical trial progress, regulatory milestones, and the eventual market need for approved therapies, rather than seasonal fluctuations.
Overview of Processa Pharmaceuticals, Inc.’s business
Processa Pharmaceuticals, Inc. (PCSA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing drug products for serious medical conditions, primarily in oncology. Their core strategy involves Next Generation Chemotherapy (NGC) oncology drug products, which are new chemical entities designed to improve the safety and efficacy of existing cancer drugs. Key products and pipeline candidates include PCS6422 (NGC-Cap) in Phase 2 trials for metastatic breast and colorectal cancer, PCS3117 (NGC-Gemcitabine) which has completed Phase 2a trials, PCS11T (NGC-Irinotecan) in pre-clinical studies, PCS12852 in Phase 2B trials for gastroparesis, and PCS499 in a Phase 2/3 study for glomerular disease.
PCSA’s Geographic footprint
Processa Pharmaceuticals, Inc.'s principal executive offices are located in Hanover, Maryland, United States. The company was founded in 2011, with some sources indicating Vero Beach, Florida, as a founding or headquarters location.
PCSA Corporate Image Assessment
Processa Pharmaceuticals has actively engaged with the scientific and investment communities through participation in major industry and scientific conferences, which generally contributes positively to its reputation. The company's focus on developing Next Generation Cancer drugs with improved safety and efficacy also positions it favorably in the oncology space. There have been no specific negative events reported that directly impact the company's brand reputation beyond the general challenges associated with stock performance.
Ownership
Processa Pharmaceuticals, Inc. has institutional owners and shareholders. As of March 3, 2026, 15 institutional owners and shareholders had filed 13D/G or 13F forms, holding a total of 115,174 shares. Major institutional owners include Jane Street Group, Llc, Vanguard Group Inc, and Hrt Financial Lp. Recent filings also show beneficial ownership by individual investors and entities such as Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC, who collectively reported beneficial ownership of 200,000 shares as of December 31, 2025. Chiliz Group also boosted its stake to 13% in February 2026.
